Skip to content


Simulect (basiliximab) is an antibody pharmaceutical. Basiliximab was first approved as Simulect on 1998-05-12. It has been approved in Europe to treat graft rejection and kidney transplantation. It is known to target interleukin-2 receptor subunit alpha.
Trade Name Simulect
Common Name Basiliximab
Indication graft rejection, kidney transplantation
Drug Class Monoclonal antibodies: chimeric, immunomodulating
Get full access now